Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 8/20 | 0.81 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.81 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.81 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.81 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 0.81 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 0.81 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.81 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.81 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.81 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 0.81 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | NQO1 | P15559 | 1/20 | 0.66 |
| ▸ | MITF | O75030 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | RAD52 | P43351 | 1/20 | 0.65 |
| ▸ | ACHE | P22303 | 1/20 | 0.64 |
| ▸ | MGAM | O43451 | 1/20 | 0.63 |
| ▸ | STAT3 | P40763 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16470737 | 0.99 | HDAC1 (0.80) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL18061333 | 0.93 | HDAC1 (0.80) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL12967988 | 0.92 | HDAC1 (0.78) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| Hydrochloric Acid SCHEMBL18241557 | 0.92 | HDAC1 (0.78) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL18254526 | 0.91 | HDAC1 (0.76) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL16489355 | 0.91 | HDAC1 (0.76) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL12967462 | 0.91 | HDAC1 (0.79) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| Hydrochloric Acid SCHEMBL16470155 | 0.90 | HDAC1 (0.75) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL16489345 | 0.90 | HDAC1 (0.79) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| Hydrochloric Acid SCHEMBL16470848 | 0.89 | HDAC1 (0.78) | HDAC1HDAC2HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3595660-B1 | COMPOUNDS FOR USE IN THE PREVENTION AND/OR TREATMENT OF NON-ALCOHOLIC FAT LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS | SJT MOLECULAR RES SL (ES) | 2023-07-05 | — | — | EP | disclosed |
| US-10857136-B2 | Compounds for use in the prevention and/or treatment of non-alcoholic fat liver disease and non-alcoholic steatohepatitis | SJT MOLECULAR RESEARCH, SL (ES) | 2020-12-08 | — | — | US | disclosed |
| US-20160340355-A1 | COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME | SJT MOLECULAR RES S L (ES) | 2016-11-24 | — | — | US | disclosed |
| US-20160340355-A1 | COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME | SJT MOLECULAR RES S L (ES) | 2016-11-24 | — | — | US | disclosed |
| US-9440966-B2 | Compounds for treatment of metabolic syndrome | SJT MOLECULAR RESEARCH, S.L. (ES) | 2016-09-13 | — | — | US | disclosed |
| US-9440966-B2 | Compounds for treatment of metabolic syndrome | SJT MOLECULAR RESEARCH, S.L. (ES) | 2016-09-13 | — | — | US | disclosed |
| US-20150051204-A1 | COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME | SJT MOLECULAR RESEARCH, S.L. (ES) | 2015-02-19 | — | — | US | disclosed |
| US-20150051204-A1 | COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME | SJT MOLECULAR RESEARCH, S.L. (ES) | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340355-A1 | COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME | GPR119, GOT2, PC | HDAC1 796/4885HDAC2 859/4885HDAC3 574/4885 |
| US-20150051204-A1 | COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME | GPR119, GOT2, PC | HDAC1 796/4885HDAC2 859/4885HDAC3 574/4885 |
| US-10857136-B2 | Compounds for use in the prevention and/or treatment of non-alcoholic fat liver disease and non-alcoholic steatohepatitis | FABP1, LIPC, SLC10A1 | HDAC1 839/4885HDAC2 1084/4885HDAC3 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.